Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1978 2
1979 2
1981 1
1982 4
1984 5
1985 5
1986 2
1987 3
1988 6
1989 2
1990 6
1991 4
1992 4
1994 3
1995 3
1996 3
1997 1
1998 5
1999 1
2000 2
2001 3
2003 1
2004 4
2005 2
2006 2
2007 7
2008 4
2009 2
2013 1
2014 1
2015 4
2016 3
2017 5
2018 2
2019 1
2020 3
2021 3
2022 1
2023 5
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Hoffstadt M, Krause T, Schweitzer A, Schnoy E, Atreya R, Teich N, Trentmann L, Ehehalt R, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: mohl w. Inflamm Bowel Dis. 2024 May 2;30(5):746-756. doi: 10.1093/ibd/izad138. Inflamm Bowel Dis. 2024. PMID: 37523666
Amending a dogma.
Mohl W, Milasinovic D, Faxon DP. Mohl W, et al. EuroIntervention. 2018 Dec 20;14(12):e1258-e1261. doi: 10.4244/EIJV14I12A227. EuroIntervention. 2018. PMID: 30566082 Free article. No abstract available.
PICSO: from myocardial salvage to tissue regeneration.
Mohl W, Gangl C, Jusić A, Aschacher T, De Jonge M, Rattay F. Mohl W, et al. Cardiovasc Revasc Med. 2015 Jan-Feb;16(1):36-46. doi: 10.1016/j.carrev.2014.12.004. Epub 2014 Dec 23. Cardiovasc Revasc Med. 2015. PMID: 25616738 Free article. Review.
117 results